Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TNM002 vs HTIG for Tetanus Antibody Titers
NCT05625477Phase 2Completed
- Sponsor
- Trinomab Pharmaceutical
- Start
- Apr 2022
- Primary completion
- May 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of siltartoxatug in Tetanus, sponsored by Trinomab Pharmaceutical. Started Apr 2022; status: completed.
02
Drugs
siltartoxatug
03
Conditions
Tetanus
Beyond the preview
Go deeper on NCT05625477.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05625477.